Posted: June 13, 2022 at 2:35 am
-70% overall response rate (ORR) and 30% complete response (CR) rate in peripheral T-cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) at Dose Level 3 (DL3) and above; clinical benefit for 90% of patients-
See the article here:
CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the...
Posted: June 13, 2022 at 2:35 am
Basel, June 12, 2022 — Novartis today announced long-term results from the ELIANA pivotal clinical trial of Kymriah® (tisagenlecleucel), the first-ever approved CAR-T cell therapy, in children and young adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL), with a maximum survival follow-up of 5.9 years. For the 79 patients treated with Kymriah in this study, the five-year overall survival (OS) rate was 55% (95% CI, 43-66), while the median event-free survival (EFS) for patients in remission within three months of infusion (n=65) was 43.8 months. These findings demonstrate the curative potential of Kymriah, the only CAR-T cell therapy available for these patients who previously had limited treatment options. These data were presented as an oral presentation during the 2022 European Hematology Association (EHA) Hybrid Congress (Abstract #S112)1.
The rest is here:
Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL
Posted: June 13, 2022 at 2:35 am
Investigational phase 3 data for Sogroya® (somapacitan) injection in children with growth hormone deficiency presented today at the ENDO 2022 Congress1
Read more here:
Novo Nordisk A/S: Sogroya® data show potential as once-weekly treatment in children living with growth hormone deficiency
Posted: June 13, 2022 at 2:35 am
Data show an overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% in the first 22 evaluable patients treated with monotherapy tovorafenib
Follow this link:
Day One Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma
Posted: June 13, 2022 at 2:35 am
REGULATED INFORMATION
More:
Bone Therapeutics to host Extraordinary General Meeting on 13 July 2022
Posted: June 13, 2022 at 2:35 am
Marseille, France, June 13, 2022 – ImCheck Therapeutics announced today the close of a EUR 96 million (USD 103 million) financing, co-led by Earlybird and Andera Partners. The Series C round (EUR 80 Million - USD 86 Million) and the last outstanding tranche of Series B converted in Series C shares (EUR 16 Million - USD 17.2 Million) solidifies ImCheck’s financial position and leadership in the gamma-delta T cell space. Invus and The Leukemia & Lymphoma Society Therapy Acceleration Program® also joined the round as new investors. Existing investors including the Growth Opportunity Fund of founding investor Kurma Partners, Eurazeo, Gimv, EQT Life Sciences (previously LSP), Boehringer Ingelheim Venture Fund, Pfizer Ventures, Bpifrance through its Innobio 2 and Large Venture funds, Wellington Partners, Agent Capital, Pureos Bioventures and Alexandria Venture Investments participated.
Posted: June 13, 2022 at 2:35 am
Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron
Follow this link:
Press Release: Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron
Posted: June 13, 2022 at 2:35 am
Guerbet receives EMA acceptance of EluciremTM as the Brand Name for Gadopiclenol.
More:
Guerbet receives EMA acceptance of EluciremTM as the Brand Name for Gadopiclenol
Posted: June 13, 2022 at 2:35 am
Stem cells are special human cells that are able to develop into many different cell types. This can range from muscle cells to brain cells. In some cases, they can also fix damaged tissues. Researchers believe that stem cell-based therapies may one day be used to treat serious illnesses such as paralysis and Alzheimer disease.
Stem cells are divided into 2 main forms. They are embryonic stem cells and adult stem cells.
Embryonic stem cells. The embryonic stem cells used in research today come from unused embryos. These result from an in vitro fertilization procedure. They are donated to science. These embryonic stem cells are pluripotent. This means that they can turn into more than one type of cell.
Adult stem cells. There are 2 types of adult stem cells.One type comes from fully developed tissues such as the brain, skin, and bone marrow. There are only small numbers of stem cells in these tissues. They are more likely to generate only certain types of cells. For example, a stem cell that comes from the liver will only make more liver cells.
The second type isinduced pluripotent stem cells. Theseare adult stem cells that have been changed in a lab to be more like embryonic stem cells. Scientists first reported that human stem cells could be changed in this way in 2006. Induced pluripotent stem cells don't seem to be different from embryonic stem cells, but scientists have not yet found one that can develop every kind of cell and tissue.
The only stem cells now used to treat disease are hematopoietic stem cells. These are the blood cell-forming adult stem cells found in bone marrow. Every type of blood cell in the bone marrow starts as a stem cell. Stem cells are immature cells that are able to make other blood cells that mature and function as needed.
These cells are used in procedures such as bone marrow transplants. These help people with cancer make new blood cells after their own hematopoietic stem cells have been killed by radiation therapy and chemotherapy. They may also be used to treat people with conditions such as Fanconi anemia. This is a blood disorder that causes the body's bone marrow to fail.
Stem cells may help your health in the future in many ways and through many new treatments. Researchers think that stem cells will be used to help create new tissue. For example, one day healthcare providers may be able to treat people with chronic heart disease. They can do this by growing healthy heart muscle cells in a lab and transplanting them into damaged hearts. Other treatments could target illnesses such as type 1 diabetes, spinal cord injuries, Alzheimer disease, and rheumatoid arthritis. New medicines could also be tested on cells made from pluripotent stem cells.
Stem cells need much more study before their use can be expanded. Scientists must first learn more about how embryonic stem cells develop. This will help them understand how to control the type of cells created from them. Another challenge is that the embryonic stem cells available today are likely to be rejected by the body. And some people find it morally troubling to use stem cells that come from embryos.
Scientists also face challenges when using adult pluripotent stem cells. These cells are hard to grow in a lab, so researchers are looking into ways to improve the process. These cells are also found in small amounts in the body. There is a greater chance that they could contain DNA problems.
Clinical trials that use stem cell therapies are currently being done in the U.S. If you are interested in trying this therapy to treat a certain condition, ask your healthcare provider how to find out about trials available in your area.
Read more:
What Are Stem Cells? - Lucile Packard Children's Hospital
Posted: June 13, 2022 at 2:35 am
Wilmington, Delaware, United States:
According to the report, the global stem cells market was valued at US$ 11.73 Bn in 2020 and is projected to expand at a CAGR of 10.4% from 2021 to 2028. Stem cells are defined as specialized cells of the human body that can develop into various different kinds of cells. Stem cells can form muscle cells, brain cells and all other cells in the body. Stem cells are used to treat various illnesses in the body.
North America was the largest market for stem cells in 2020. The region dominated the global market due to substantial investments in the field, impressive economic growth, increase in incidence of target chronic diseases, and technological progress. Moreover, technological advancements, increase in access to healthcare services, and entry of new manufacturers are the other factors likely to fuel the growth of the market in North America during the forecast period.
Request Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132
Asia Pacific is projected to be a highly lucrative market for stem cells during the forecast period. The market in the region is anticipated to expand at a high CAGR during the forecast period. High per capita income has increased the consumption of diagnostic and therapy products in the region. Rapid expansion of the market in the region can be attributed to numerous government initiatives undertaken to improve the health care infrastructure. The market in Asia Pacific is estimated to expand rapidly compared to other regions due to shift in base of pharmaceutical companies and clinical research industries from developed to developing regions such as China and India. Moreover, changing lifestyles and increase in urbanization in these countries have led to a gradual escalation in the incidence of lifestyle-related diseases such as cancer, diabetes, and heart diseases.
Technological Advancements to Drive Market
Several companies are developing new approaches to culturing or utilizing stem cells for various applications. Stem cell technology is a rapidly developing field that combines the efforts of cell biologists, geneticists, and clinicians, and offers hope of effective treatment for various malignant and non-malignant diseases. The stem cell technology is progressing as a result of multidisciplinary effort, and advances in this technology have stimulated a rapid growth in the understanding of embryonic and postnatal neural development.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=132
Adult Stem Cells Segment to Dominate Global Market
In terms of product type, the global stem cells market has been classified into adult stem cells, human embryonic stem cells, and induced pluripotent stem cells. The adult stem cells segment accounted for leading share of the global market in 2020. The capability of adult stem cells to generate a large number of specialized cells lowers the risk of rejection and enables repair of damaged tissues.
Autologous Segment to Lead Market
Based on source, the global stem cells market has been bifurcated into autologous and allogenic. The autologous segment accounted for leading share of the global market in 2020. Autologous stem cells are used from ones own body to replace damaged bone marrow and hence it is safer and is commonly being practiced.
Request for Analysis of COVID19 Impact on Stem Cells Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=132
Regenerative Medicines to be Highly Lucrative
In terms of application, the global stem cells market has been categorized into regenerative medicines (neurology, oncology, cardiology, and others) and drug discovery & development. The regenerative medicines segment accounted for major share of the global market in 2020, as regenerative medicine is a stem cell therapy and the medicines are made using stem cells in order to repair an injured tissue. Increase in the number of cardiac diseases and other health conditions drive the segment.
Therapeutics Companies Emerge as Major End-users
Based on end-user, the global stem cells market has been divided into therapeutics companies, cell & tissue banks, tools & reagents companies, and service companies. The therapeutics companies segment dominated the global stem cells market in 2020. The segment is driven by increase in usage of stem cells to treat various illnesses in the body. Therapeutic companies are increasing the utilization of stem cells for providing various therapies. However, the cell & tissue banks segment is projected to expand at a high CAGR during the forecast period. Increase in number of banks that carry out research on stem cells required for tissue & cell growth and elaborative use of stem cells to grow various cells & tissues can be attributed to the growth of the segment.
Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=132
Regional Analysis
In terms of region, the global stem cells market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global stem cells market in 2020, followed by Europe. Emerging markets in Asia Pacific hold immense growth potential due to increase in income levels in emerging markets such as India and China leading to a rise in healthcare spending.
Competition Landscape
The global stem cells market is fragmented in terms of number of players. Key players in the global market include STEMCELL Technologies, Inc., Astellas Pharma, Inc., Cellular Engineering Technologies, Inc., BioTime, Inc., Takara Bio, Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics, Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc.
More Trending Reports by Transparency Market Research
Regulatory Affairs Outsourcing Market: https://www.transparencymarketresearch.com/global-regulatory-affairs-outsourcing-market.html
Equine Healthcare Market: https://www.transparencymarketresearch.com/equine-healthcare-market.html
Home Healthcare Market: https://www.transparencymarketresearch.com/home-healthcare-market.html
Triclabendazole Market: https://www.transparencymarketresearch.com/triclabendazole-market.html
Brucellosis Vaccine Market: https://www.transparencymarketresearch.com/brucellosis-vaccines-market.html
Solitary Fibrous Tumor Treatment Market: https://www.transparencymarketresearch.com/solitary-fibrous-tumor-treatment-market.html
Post operative Pain Therapeutics Market: https://www.transparencymarketresearch.com/postoperative-pain-therapeutics-market.html
ACL Reconstruction Procedures Market: https://www.transparencymarketresearch.com/acl-reconstruction-procedures-market.html
About Us
Transparency Market Research is a global market intelligence company providing market research reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact Us
Rohit Bhisey
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/
Follow this link:
Stem Cells Market to Cross US$ 25.68 Bn by 2028, Increasing Demand for Stem Cells in Regenerative Medicines Accelerates Market Growth - BioSpace
